Welcome to our dedicated page for Morphosys news (Ticker: MPSYF), a resource for investors and traders seeking the latest updates and insights on Morphosys stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Morphosys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Morphosys's position in the market.
MorphoSys AG announced an update regarding its licensing partner GSK and the ContRAst phase III program for otilimab, aimed at treating moderate to severe rheumatoid arthritis. The trials ContRAst-1 and ContRAst-2 successfully met primary endpoints, showing significant ACR20 responses. However, ContRAst-3 did not meet its primary endpoint, leading GSK to conclude that otilimab does not present a suitable benefit/risk profile for regulatory submission. GSK plans to publish the full results in 2023.
MorphoSys reported preliminary U.S. net product sales of Monjuvi at US$ 22.2 million for Q3 2022, totaling US$ 64.1 million for the first nine months. The company has revised its full-year sales guidance for Monjuvi to approximately US$ 90 million, down from US$ 90 to US$ 110 million, due to increased competition in the treatment of diffuse large B-cell lymphoma. The gross margin for Monjuvi remains at 75% to 80%. Full financial results will be released on November 16, 2022.
MorphoSys AG will publish its Q2 and H1 2022 financial results on August 3, 2022, at 10:00 PM CEST. A conference call is scheduled for August 4, 2022, at 2:00 PM CEST, where the management team will discuss the results and provide an outlook for the year. Investors can access the live webcast and presentation on the company’s website. The call will include a Q&A session and a replay will be available post-event. MorphoSys is committed to advancing cancer treatments through its innovative biopharmaceuticals.
MorphoSys AG reported preliminary Q2 2022 U.S. net product sales of Monjuvi totaling US$ 23.3 million, achieving US$ 41.9 million in sales for the first half of 2022. The company updated its full-year sales guidance for Monjuvi to US$ 90 to 110 million, down from the previous range of US$ 110 to 135 million. R&D expense guidance was lowered to €275 to 300 million due to licensing agreements for felzartamab and MOR210. SG&A expenses are now expected to be €150 to 165 million.
MorphoSys AG reported preliminary Q2 2022 U.S. net product sales of Monjuvi amounting to US$ 23.3 million and US$ 41.9 million for the first half of 2022. The company has updated its 2022 financial guidance, projecting Monjuvi net sales between US$ 90 million and US$ 110 million, down from US$ 110 million to US$ 135 million. Additionally, R&D expenses are now estimated at €275 million to €300 million, and SG&A expenses at €150 million to €165 million. Full results will be published on August 3, 2022.